00:16:12 EDT Sun 13 Oct 2024
Enter Symbol
or Name
USA
CA



Login ID:
Password:
Save
Numinus Wellness Inc
Symbol NUMI
Shares Issued 266,455,100
Close 2024-01-31 C$ 0.14
Market Cap C$ 37,303,714
Recent Sedar Documents

Numinus Wellness corrects asset divestment

2024-02-01 15:21 ET - News Release

Mr. Payton Nyquvest reports

CORRECTION: NUMINUS WELLNESS DIVESTS OF HOLDINGS IN CO-INVESTMENT FEEDER FUND 3

Numinus Wellness Inc. has made a correction to its press release entitled issued on Feb. 1, 2024.

The initial press release incorrectly announced a sale of shares. The correct asset divested by Numinus is units of Co-Investment Feeder Fund 3, a subfund of Apeiron Feeder SICAV PLC, in a transfer of limited partnership interests to another LP of the subfund. The investment was included in the company's acquisition of Novamind Inc. on June 10, 2022. The divestiture was made to unlock operating capital and is part of the company's strategic road map to focus on key revenue-generating initiatives and enhance operational efficiency to drive toward improved long-term performance and create stabilization in the current environment.

"We are happy to announce this divestiture as we continue to focus on our core business and drive shareholder value creation more broadly," said Payton Nyquvest, founder and chief executive officer of Numinus. "As our core strategy is to build the critical infrastructure that addresses the growing need for effective mental health treatments, the proceeds from the sale of this non-core asset will provide additional financial liquidity and flexibility. Our continued focus on driving growth and optimizing operations will enable us to apply these funds efficiently while the management team remains focused on achieving profitability with our continuing operations."

About Numinus Wellness Inc.

Numinus Wellness helps people to heal and be well through the development and delivery of innovative mental health care and access to safe, evidence-based psychedelic-assisted therapies. The Numinus model -- including psychedelic research and clinic care -- is at the forefront of a transformation aimed at healing rather than managing symptoms for depression, anxiety, trauma, pain and substance use. At Numinus, the company is leading the integration of psychedelic-assisted therapies into mainstream clinical practice and building the foundation for a healthier society.

We seek Safe Harbor.

© 2024 Canjex Publishing Ltd. All rights reserved.